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Sarcoidosis is a disease of unknown etiology characterized by noncaseating epithelioid 
granulomas, oligoclonal CD4
 
  
 
T cell infiltrates, and immune complex formation. To identify 
pathogenic antigens relevant to immune-mediated granulomatous inflammation in 
sarcoidosis, we used a limited proteomics approach to detect tissue antigens that were 
poorly soluble in neutral detergent and resistant to protease digestion, consistent with the 
known biochemical properties of granuloma-inducing sarcoidosis tissue extracts. Tissue 
antigens with these characteristics were detected with immunoglobulin (Ig)G or F(ab
 
 
 
)
 
2 
 
fragments from the sera of sarcoidosis patients in 9 of 12 (75%) sarcoidosis tissues (150–160, 
80, or 60–64 kD) but only 3 of 22 (14%) control tissues (all 62–64 kD; P 
 
  
 
0.0006). 
Matrix-assisted laser desorption/ionization time of flight mass spectrometry identified 
 
Mycobacterium tuberculosis 
 
catalase–peroxidase (mKatG) as one of these tissue antigens. 
Protein immunoblotting using anti-mKatG monoclonal antibodies independently confirmed 
the presence of mKatG in 5 of 9 (55%) sarcoidosis tissues but in none of 14 control tissues 
(P 
 
  
 
0.0037). IgG antibodies to recombinant mKatG were detected in the sera of 12 of 25 
(48%) sarcoidosis patients compared with 0 of 11 (0%) purified protein derivative (PPD)
 
  
 
(P 
 
  
 
0.0059) and 4 of 10 (40%) PPD
 
  
 
(P 
 
  
 
0.7233) control subjects, suggesting that 
remnant mycobacterial catalase–peroxidase is one target of the adaptive immune response 
driving granulomatous inflammation in sarcoidosis.
 
Sarcoidosis is recognized as an immune-mediated
granulomatous disease because tissue inflam-
mation  involves activated CD4
 
  
 
T cells and
mononuclear cells with giant cell formation
(1). This inflammatory response is associated
with marked skewing of the cytokine response
toward a Th1 cell cytokine profile with en-
hanced expression of IFN-
 
 
 
, IL-2, and TNF
along with the Th1 cell regulatory cytokines,
IL-12 and IL-18 (2–4). Studies of TCR gene
expression in sarcoidosis provide evidence that
oligoclonal populations of 
 
  
 
  
 
CD4
 
  
 
T cells
collect at sites of granulomatous inflammation,
consistent with an MHC-restricted antigen-
driven response (5–7). Concomitant stimulation
of the adaptive B cell response in sarcoidosis is
evidenced by the immune complex formation
found in 70–100% of patients early in this disor-
der (8). Although the identity of the stimulat-
ing antigens in sarcoidosis remains unknown,
experimental models indicate that adaptive Th1/
Th2 cell responses mediate immune-mediated
granulomatous inflammation (9, 10).
A major step in understanding the etio-
pathogenesis of sarcoidosis would be the identi-
fication of specific antigens contributing to the
adaptive immune response mediating granulo-
matous inflammation in this disease. To identify
potential target antigens of the adaptive immune
response in sarcoidosis, we have capitalized on
the observation that homogenates of diseased
tissue injected intradermally in patients with sar-
coidosis elicit a nidus of granulomatous inflam-
mation that is indistinguishable from spontane-
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ously arising granulomas, known as the Kveim (or Kveim-
Siltzbach) reaction (11–13). In this reaction, well-formed epi-
thelioid granulomas develop after 2–4 wk. In timing and his-
topathology, this granulomatous response is analogous to the
Mitsuda reaction to lepromins in tuberculoid leprosy (14).
Early studies found circulating antibodies were directed against
the Kveim reagent, consistent with a humoral response to an-
tigens present in sarcoidosis tissue (15). Our own studies dem-
onstrated the presence of expanded populations of clonal T
cells at Kveim reaction sites, consistent with antigen-specific
responses to components in Kveim extracts (16). Biochemical
characteristics of granuloma-inducing Kveim extracts include
neutral detergent insolubility, relative heat, acid, and protease
resistance, and sensitivity to potent denaturants, consistent
with poorly soluble protein aggregates (17, 18). In this study,
we used a limited proteomic approach with protein immuno-
blot and matrix-assisted laser desorption/ionization time of
flight (MALDI-TOF) mass spectrometry to identify potential
antigenic targets in sarcoidosis tissue that may contribute to
immune-mediated granulomatous inflammation in sarcoidosis.
 
RESULTS
Protease-resistant proteins in sarcoidosis tissues are targets 
of circulating IgG
 
To enrich for tissue antigens associated with sarcoidosis granu-
loma formation, we used the known biochemical properties of
active Kveim reagent to limit the target proteome by preparing
Triton X-100 (TX100) detergent-insoluble extracts of sarcoi-
dosis and control lymph node homogenates with or without
proteinase K (PK) digestion (17, 18). When non-PK–treated
tissue extracts were solubilized and analyzed by protein immu-
noblot, multiple antigenic bands were seen using sarcoidosis or
control total IgG or F(ab
 
 
 
)
 
2 
 
fragments detected with anti-Fc or
anti-Fab reagents (Fig. 1). When the same sarcoidosis tissue ho-
mogenates were digested with PK overnight, we found discrete
bands in six of nine (67%) lymph node, one lung, and two
spleen samples that were not detected with secondary antibody
alone (Table I and Fig. 1, A–D). The antigenic bands varied in
size with 60-, 62–64-, 80-, or 
 
 
 
150–160-kD bands seen in dif-
ferent samples (Table I). In one of these samples, the 62–64-kD
bands (but not other bands) were detected with control sera.
Analysis of nonsarcoidosis control tissues demonstrated that only
1 of 11 (9%) lymph node, 1 of 5 (20%) splenic, and 0 of 1 lung
samples with PK-resistant antigenic bands were detected using
sarcoidosis sera as detecting reagent. In both of these cases, 62–
64-kD bands were seen, suggesting that these antigens were not
exclusive to sarcoidosis tissues. Overall, 9 of 12 (75%) sarcoido-
sis tissue samples but only 2 of 17 (12%) control tissue samples
contained TX100-insoluble, PK-resistant antigenic bands de-
tected with sarcoidosis IgG or F(ab
 
 
 
)
 
2 
 
fragments (P 
 
  
 
0.0013).
 
Sarcoidosis tissue antigens are poorly soluble in a 
moderately denaturing detergent
 
In addition to the TX100 detergent extraction method to
isolate potential disease-relevant antigens in sarcoidosis tis-
sues, as a second approach we used a sarkosyl-based extrac-
tion procedure designed to enrich for poorly soluble protein
(prion) aggregates (19). Two sarcoidosis and seven control
samples with sufficient amounts of tissue to complete this
protocol were analyzed. We found multiple antigenic bands
in the initial insoluble fraction (P22) and intermediate super-
natant fraction (S215) from both sarcoidosis and control tis-
sues using sarcoidosis IgG reagents (Fig. 2). When the final
precipitated cell pellets (Pe) were solubilized and subjected
to protein immunoblotting, we found antigenic bands in
both of the sarcoidosis tissues (Fig. 2 and Table I). The sar-
coidosis spleen sample demonstrated four antigenic bands
similar in size to those detected using the TX100/PK diges-
tion protocol (Fig. 2 A and Table I). The sarcoidosis lung
sample yielded antigenic bands (60, 62, and 
 
 
 
160 kD) in the
final Pe fraction (Fig. 2 B and Table I). The Pe fractions
Figure 1. Protease-resistant proteins in sarcoidosis tissues are tar-
gets of circulating IgG from patients with sarcoidosis. TX100-insoluble 
detergent extracts from sarcoidosis (S) and control (C) lymph nodes were 
treated with or without PK and subjected to denaturing SDS-PAGE and 
immunoblot analysis with purified IgG or F(ab )2 fragments from pooled 
control or sarcoidosis sera detected with anti–human Fc  or Fab reagents, 
respectively. Four separate immunoblots (A–D) with samples corresponding 
to Table I are shown. Immunoblots in A and B were probed with control 
reagents, stripped, and then reprobed with sarcoidosis reagents. Numbers 
give molecular mass in kilodaltons (kD). Arrows demark antigenic bands in 
PK-treated sarcoidosis tissues when probed with sarcoidosis serologic 
reagents but not control reagents or secondary antibody alone. 
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Table I.
 
Summary of antigenic bands from protein immunoblots of extracts of sarcoidosis and control tissues
 
Detecting sera
Sample Pathology Extraction Sarcoidosis Control
Antigenic bands
(kD)
Anti-mKatG
(IT57)
 
Sarcoidosis
S1 LN
 
a
 
NCG
 
b
 
TX100
 
 
 
c
 
 
 
none
 
 
 
S2 LN NCG TX100
 
  
 
60
 
 
 
S3 LN NCG TX100
 
 
 
ND 62, 64
 
 
 
S4 LN NCG TX100
 
 
 
ND none ND
S5 LN NCG TX100
 
  
 
62, 64
 
 
 
S6 LN NCG TX100
 
 
 
ND 62, 64, 80
 
 
 
S7 LN NCG TX100
 
 
 
ND
 
 
 
160 ND
S8 LN NCG TX100
 
  
 
62 ND
S9 LN no gran
 
d
 
TX100
 
  
 
none
 
 
 
S10 SPL
 
e
 
NCG TX100
 
  
 
60, 62
 
 
 
S11 SPL NCG TX100
 
  
 
60, 62
 
f
 
, 64
 
f
 
, 150, 160
Sarkosyl
 
  
 
60, 62
 
f
 
, 64
 
f
 
, 150, 160
 
 
 
S12 LU
 
g
 
NCG TX100
 
 
 
ND
 
 
 
160
Sarkosyl
 
  
 
60, 62, 
 
 
 
160
 
 
 
Controls
C1 LN no path
 
h
 
TX100
 
  
 
none ND
C2 LN no path TX100
 
  
 
62
 
 
 
C3 LN no path TX100
 
  
 
none
 
 
 
C4 LN no path TX100
 
  
 
none
 
 
 
C5 LN no path TX100
 
  
 
none
 
 
 
C6 LN FH
 
i
 
TX100
 
  
 
none
 
 
 
C7 LN FH TX100
 
 
 
ND none ND
C8 LN no path TX100
 
 
 
ND none
 
 
 
C9 LN no path TX100
 
 
 
ND none
 
 
 
C10 LN no path TX100
 
  
 
none
 
 
 
C11 LN no path TX100
 
 
 
ND none ND
C12 SPL no path TX100
 
 
 
ND none
 
 
 
C13 SPL no path TX100
 
  
 
none
 
 
 
C14 SPL no path Sarkosyl
 
 
 
ND none ND
C15 SPL no path Sarkosyl
 
  
 
none ND
C16 SPL no path Sarkosyl
 
  
 
none ND
C17 SPL no path Sarkosyl
 
 
 
ND none
 
 
 
C18 SPL no path TX100
 
  
 
none
 
 
 
C19 SPL no path TX100
 
 
 
ND none
Sarkosyl
 
  
 
62
 
f
 
, 64
 
f  
C20 SPL no path Sarkosyl    none ND
C21 SPL no path TX100   ND 62, 64 ND
C22 LU no path TX100   ND none  
Sarkosyl   ND none  
aLymph node.
bNoncaseating granuloma.
c , no clearly detectable band;  , presence of bands not seen with secondary antibody alone.
dNo granuloma.
eSpleen.
fBands also seen with control sera.
gLung.
hNo tumor, granuloma, or other identified pathology.
iFollicular hyperplasia.MYCOBACTERIAL CATALASE–PEROXIDASE IN SARCOIDOSIS | Song et al. 758
Table II. Summary of peptide matches for mKatG using MALDI-TOF mass spectrometry of sarcoidosis spleen tissuea
m/z submitted MH  matched   ppm Start End Peptide sequence
562.5000 562.2949 364.7568 485 489 (R)GSDKR(G)
833.2000 833.4634  315.9844 687 693 (K)VKWTGSR(V)
1163.7000 1163.5420 135.7729 105 114 (R)MAWHAAGTYR(I)
1437.1000 1437.7603  459.2364 558 571 (K)AAGHNITVPFTPGR(T)
1475.9000 1475.7382 109.6406 706 719 (R)ALVEVYGADDAQPK(F)
1708.3000 1707.9295 216.9512 555 571 (K)AAKAAGHNITVPFTPGR(T)
1713.9000 1713.8124 51.0985 397 410 (R)WLEHPEELADEFAK(A)
1741.6000 1741.8345  134.6375 105 119 (R)MAWHAAGTYRIHDGR(G)
1774.3000 1774.7938  278.2053 28 42 (K)YPVEGGGNQDWWPNR(L)
1869.8000 1869.9135  60.7182 396 410 (R)RWLEHPEELADEFAK(A)
1901.1000 1901.9510  447.4279 129 145 (R)FAPLNSWPDNASLDKAR(R)
1947.0000 1947.9664  496.0873 520 537 (R)TLEEIQESFNSAAPGNIK(V)
2018.9000 2018.0963 398.2698 596 613 (R)NYLGKGNPLPAEYILLDK(A)
2342.3000 2343.1517  363.5002 159 179 (K)LSWADLIVFAGNCALESMGFK(T)
2445.2000 2446.1574  391.3758 120 143 (R)GGAGGGMQRFAPLNSWPDNASLDK(A)
2470.5000 2471.2467  302.1548 158 179 (K)KLSWADLIESMGFK(T)
aPeptides from the high salt precipitate are shown if both low and high salt precipitates resulted in peptide peaks of similar size ( 1 dalton).
from five of six control spleens (Fig. 2 A) and one control
lung (not depicted) that were processed in parallel contained
little detectable protein and did not demonstrate antigenic
bands using either sarcoidosis or control IgG reagents (Table
I). One control spleen sample demonstrated 62–64-kD
bands reactive with both sarcoidosis and control sera. Over-
all, combining results from both the sarkosyl and TX100 ex-
traction procedures, we found that 9 of 12 (75%) sarcoidosis
tissue samples versus 3 of 22 (14%) control tissue samples
demonstrated antigenic bands detected by sarcoidosis sera on
immunoblot analysis (P   0.0006).
Identification of candidate pathogenic antigens using 
MALDI-TOF mass spectrometry
To identify these candidate pathogenic tissue antigens, two
sarcoidosis tissues with sufficient amounts of remaining pro-
cessed material were analyzed. Gel slices of the approximate
size of the antigenic bands were excised, subjected to in situ
trypsin digestion, and analyzed by MALDI-TOF mass spec-
trometry. The mass spectrum of the trypsin digest of a 60–
62-kD sized gel slice from the Pe fraction from a sarcoidosis
spleen extract (Fig. 2 A, S11) demonstrated multiple peaks
that were not present in the trypsin control samples, consis-
tent with a complex mixture of peptides. When the peptide
mass fingerprints were submitted for protein database se-
quence analyses, the highest match was for Mycobacterium
tuberculosis (Mtb) catalase–peroxidase (mKatG; mol wt  
80,625; Genpept accession no. U06265). Under low salt
precipitation, 8 of 31 (25%) peptide peaks matched this pro-
tein (mol wt search [MOWSE] score of 4.89   10e 03).
For the combined low and high salt peptide precipitations,
16 of 74 peptides matched the peptide fingerprint of mKatG
(MOWSE score of 1.07   10e 09; Mascot score of 71;
P   0.05; Table II). Consistent with the presence of myco-
Figure 2. Sarcoidosis tissues extracted with sarkosyl contain poorly 
soluble protein antigens that bind to sarcoidosis IgG. (A) Protein frac-
tions from sarcoidosis (S) or control (C) spleen. (B) Protein fractions from 
sarcoidosis lung. Protein fractions were analyzed by protein immunoblotting 
using purified IgG from sarcoidosis sera detected with anti–human Fc  
reagents. The initial homogenates (P22), intermediate supernatant fractions 
(S215, S1, and S2), or final cell pellets that were poorly soluble in sarkosyl 
(Pe) are shown. Pe were solubilized using 8 M urea plus  -mecaptoethanol 
and were precipitated before analysis by gel electrophoresis. Arrows point 
to antigenic bands seen in the Pe fractions of sarcoidosis but not control 
tissues. Arrowhead points to a 56-kD band detected with anti-Fc  reagents 
alone in the Pe fraction from sarcoidosis lung (B).JEM VOL. 201, March 7, 2005 759
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bacterial antigens in this sample, when the 16 fragments
that matched mKatG were removed and the search was re-
peated, a top potential match was found to Mtb topoisomerase
I with 9 matching peptides (Genpept accession no. U40159;
MOWSE score of 8.38e 005; Table S1, available at http://
www.jem.org/cgi/content/full/jem.20040429/DC1).
Next, we performed MALDI-TOF mass spectrometric
analysis of a trypsin digest of a 60–62-kD band excised from
the gel of the Pe fraction of a sarcoidosis lung sample from a
different patient (Fig. 2 B, S12). Although there was not a
single high probability match of the peptide fingerprint from
this sample to the database, the MALDI-TOF mass spectrum
matched 4 of 26 peptide fragments from Mycobacterium smeg-
matis KatG (MOWSE score of 1.39   10e 03; Genpept
accession no. 11255575; Table S2). Three other potential
antigenic bands ( 64, 150, and 160 kD) from this sample
provided no statistically significant matches. When gel slices
of 60–62 kD in size were excised from five control tissue ex-
tracts, the mass spectra demonstrated few peaks, all of very
low intensity, that were insufficient for mass spectra finger-
printing analysis.
Confirmation of the presence of mKatG protein in 
sarcoidosis tissue by protein immunoblot
To independently validate the mKatG results from the pep-
tide fingerprinting analyses and assess the hypothesis that
mKatG is a common tissue antigen in sarcoidosis, we ana-
lyzed protein immunoblots of sarcoidosis and control tissue
extracts using the IT57 mAb reactive to mKatG (20). For
reference, recombinant mKatG was denatured by ethanol
precipitation and analyzed by protein immunoblot along
with heat-sonicated extracts from several mycobacterial and
bacterial extracts (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20040429/DC1). The IT57 mAb re-
acted strongly to recombinant mKatG, detecting both the
 80-kD monomer and a  160-kD protein, consistent with
homodimer formation known for its native form (21, 22).
Additional   140-, 60-, 56-, and 40-kD peptides derived
from mKatG as determined by MALDI-TOF mass spec-
trometry were also seen (not depicted). The IT57 mAbs re-
acted strongly to  80- and  160-kD proteins from Mtb and
M. smegmatis extracts but did not bind to proteins from My-
cobacterium chelonei, Helicobacter pylori, or Escherichia coli (Fig.
S1). Protein immunoblots of the same sarcoidosis spleen
sample (S11) from which mKatG peptides were detected by
MALDI-TOF mass spectrometry demonstrated  80- and
 160-kD bands, consistent with monomer and homodimer
forms of mKatG (Fig. 3). Five control splenic tissues that
were processed similarly did not have detectable bands on
immunoblot analysis (Fig. 3, C14). Reprobing an immuno-
blot of the sarcoidosis lung homogenate that yielded a possible
match to M. smegmatis KatG on MALDI-TOF mass spec-
trometry demonstrated a faint band of an  80-kD size. A
control lung sample did not bind to IT57 mAb (not de-
picted). Three of eight (38%) sarcoidosis lymph node but
none of the eight (0%) control lymph node samples had de-
tectable bands, consistent with the presence of mKatG pro-
tein (Fig. 3, S2 and C2). Other tissue samples could not be
reanalyzed because of technically inadequate reprobing of ar-
chived immunoblots or lack of biopsy tissue. Overall, 5 of 9
(56%) sarcoidosis tissues compared with 0 of 14 (0%) control
tissues had detectable mKatG on protein immunoblotting
using anti-mKatG mAbs (P   0.0037).
In situ hybridization (ISH) demonstrates Mtb katG and 16S 
rRNA DNA in sarcoidosis tissues
To further substantiate the potential significance of mKatG
as a tissue antigen in sarcoidosis, we examined archival bi-
opsy tissues for mkatG DNA. Using ISH–tyramide signal
amplification (TSA), mkatG DNA was detected in 7 of 18
(39%) sarcoidosis and 4 of 4 Mtb-infected tissues but not in 0
of 18 control tissues that included 5 biopsies from patients
with Wegener granulomatosis (sarcoidosis vs. nontubercu-
lous controls; P   0.0076; Fig. 4 and Table III). Reverse
DNA probes and probes from H. pylori 16S rRNA were
negative in all samples. ISH without signal amplification us-
ing probes derived from Mtb 16S rRNA confirmed the pres-
ence of mycobacterial DNA in 5 of 6 (83%) mKatG  sam-
ples and overall in 6 of 16 (38%) sarcoidosis tissues compared
with 0 of 16 (0%) control tissues (P   0.018; Fig. 5 and Ta-
ble III). Reverse Mtb 16S rRNA probes were uniformly
negative in all samples.
Sarcoidosis IgG binds recombinant mKatG
To determine the extent to which mKatG is a relevant
pathogenic antigen in sarcoidosis, we analyzed sera from sar-
coidosis patients and purified protein derivative (PPD)  and
PPD  control individuals for binding to recombinant
mKatG. We found circulating anti-mKatG IgG in the sera of
12 of 25 (48%) sarcoidosis patients compared with 0 of 11
(0%) PPD  healthy control individuals (P   0.0059) and 4 of
10 (40%) PPD  individuals (P   0.7233; overall group com-
Figure 3. Immunoblot analysis confirms the presence of mKatG 
protein in sarcoidosis tissue. Shown are individual protein immunoblots 
of recombinant mKatG, sarkosyl-extracted sarcoidosis (S11), or control 
(C14) spleen extracts or TX100-insoluble sarcoidosis (S2) or control (C2) 
lymph node extracts using the IT57 anti-mKatG mAb. Arrowheads demark 
migration of corresponding mol wt. markers.MYCOBACTERIAL CATALASE–PEROXIDASE IN SARCOIDOSIS | Song et al. 760
parison, P   0.0034; Fig. 6 A and complete data in Table
IV). Circulating IgG from both sarcoidosis patients and
PPD  individuals bound to either 80- or 60-kD mKatG-
migrating proteins or both. Two sarcoidosis patients and one
PPD  individual had positive mKatG immunoblots with se-
rologic titers  1:1,000 (Table IV). Sarcoidosis patients with
circulating IgG to mKatG were clinically diverse, including
those with and without extrapulmonary involvement. There
was no correlation between the presence or absence of anti-
mKatG IgG and the radiographic stage of the same patient
(Table IV; P   0.9289).
To determine whether reactivity to mKatG was selective
in sarcoidosis or associated with reactivity to other mycobac-
terial proteins, we analyzed circulating IgG binding to re-
combinant Mycobacterium bovis Hsp65 protein (mHsp65) in
these groups. We found circulating IgG binding to mHsp65
Figure 4. Cellular localization of mkatG DNA by ISH with TSA. 
Shown are representative photomicrographs from biopsies of Mtb-infected 
tissue (A–C), normal controls (no pathology; D–F), Wegener granulomatosis 
(G–I), and sarcoidosis tissues (J–O). Tissue sections were hybridized with or 
without DIG-labeled probes, detected with anti-DIG F(ab )2 fragments 
conjugated with HRP, and the signal was amplified by incubation with 
biotinylated tyramine followed by streptavidin conjugated to HRP and a 
DAB chromogen solution. Mtb-infected tissue (A) and sarcoidosis samples 
(J and M) demonstrated focal collections of mkatG DNA that were not 
seen in biopsies from Wegener granulomatosis (G) nor in nongranuloma-
tous control tissues (D). All tissues were negative using reverse mkatG and 
H. pylori 16S rRNA probes (C, inset, positive H. pylori control).JEM VOL. 201, March 7, 2005 761
ARTICLE
Table III. Quantification of focal collections of mkatG and Mtb 16S rRNA DNA in sarcoidosis and control tissues
mkatG
forward probe
Mtb 16S rRNA
forward probe
H. pylori 16S rRNA
forward probe
Group Sample Tissue Pathologya  Fields viewedb
Focal
collectionsc Interpretationd
Focal
collectionsc Interpretationd
Focal
collectionsc Interpretationd
Mtb 1 pleura CAS   NC 32 6   0  
2 lung CAS   NC 14 3   0   0  
3 liver CAS   NC 32  30   10   0  
4 lung CAS   NC 32  30   10   0  
Control 1 lung diff-GC 40 0   0   0  
Wegener
granulomatosis
2 lung diff-GC 24 0   0   0  
3 lung diff-GC 40 0   0   0  
4 lung diff-GC 32 1   0   0  
5 lung diff-GC 28 0  
Control 1 lung F 36 0   0   0  
UIP 2 lung Int   F2 4 0   0   0  
3 lung F 24 0   0   0  
4 lung F 24 0   0  
Control 1 lung none 24 0   0   0  
No pathology 2 lung none 24 0   0   0  
3 lung none 20 0   0   0  
4 lung none 20 0   0   0  
5 LN none 36 0   0   0  
6 LN none 24 0   0   0  
7 LN none 24 0   0   0  
8 LN none 24 0   0   0  
9 LN none 20 0   0   0  
Sarcoidosis 1 lung NC 48 12   5   0  
2 lung NC   F2 02 6   3   0  
3 lung NC   F3 2 0   3 indeterminate 0  
4 lung NC 20 0   0   0  
5 lung NC 40 0   2 indeterminate 0  
6 lung NC 40 4 indeterminate 0   0  
7 lung NC   F 20 1 indeterminate 1 indeterminate 0  
8 lung NC 20 0  
9 lung NC 20 0   0   0  
10 lung NC 20 6   1 indeterminate 0  
11 lung NC 28 5   3   0  
12 LN NC 32 9   0  
13 LN NC 28 7   3   0  
14 LN NC 28 2 indeterminate 4  
15 LN NC 36 0   3 indeterminate 0  
16 LN NC 28 5   3   0  
17 LN NC 16 0   0   0  
18 LN NC 16 0   1 indeterminate 0  
aCAS, caseous granulomatous inflammation; NC, noncaseating granulomatous inflammation; diff-GC, diffuse granulomatous inflammation with giant cells; Int, cellular inter-
stitial infiltrate; F, fibrosis.
bNumber of high power fields (400 ) viewed for analysis.
cNumber of focal collections of ISH staining (positive signal).
dNegative,  0.5 focal collections per 10 high power fields examined; indeterminate, 0.5–1.0 focal collections per 10 high power fields examined; positive,  1.0 focal collections 
per 10 high power fields examined.MYCOBACTERIAL CATALASE–PEROXIDASE IN SARCOIDOSIS | Song et al. 762
in all PPD  subjects (10 of 10), in 6 of 11 (55%) PPD  con-
trols, and in 17 of 25 (68%) sarcoidosis patients (group com-
parison, P    0.0129; PPD  vs. sarcoidosis, P    0.0363;
PPD  vs. PPD , P    0.0351; Fig. 6 B and Table III).
Within the sarcoidosis group, all 12 mKatG  sera also bound
to mHsp65, suggesting the presence of reactivity to myco-
bacterial antigens other than mKatG in this subset of pa-
tients. The proportion of sarcoidosis patients with reactivity
to mHsp65 but not mKatG (6 of 12 [50%]) was not statisti-
cally different from PPD  controls (P   0.9), suggesting a
nondisease-specific reactivity or cross-reactivity to mHsp65
in these patients.
DISCUSSION
The studies presented here demonstrate the existence of a
small number of protease-resistant, poorly soluble antigens in
sarcoidosis tissues that are targets of an adaptive T cell–
dependent IgG response in patients with this disease. Sarcoi-
dosis-specific target antigens were discriminated from anti-
gens in control tissues by using a limited proteomic approach
that preferentially concentrated proteins resistant to protease
digestion in neutral detergent, or by selecting for poorly solu-
ble protein aggregates using a moderately denaturing deter-
gent extraction method. The fact that these biochemical
treatments are known to preserve and concentrate the in
vivo granuloma-inducing activity of sarcoidosis tissue homog-
enates enhances the probability that these specific tissue an-
tigens are relevant to the disease pathogenesis. More impor-
tantly, we identified one of these candidate antigenic targets
to be derived from the mycobacterial KatG protein. This
identification was initially made by MALDI-TOF mass spec-
trometric peptide fingerprinting but was critically verified
using specific anti-mKatG mAbs and immunoblot analysis.
Further support for these findings was provided by the de-
tection of mKatG DNA using ISH techniques in a subset of
sarcoidosis tissues. Together, these results provide evidence
that poorly soluble protein aggregates containing mKatG are
present in a subset of sarcoidosis tissues, representing a po-
tential target for local adaptive immune responses.
The mycobacterial catalase–peroxidase protein encoded
by  katG is found in most mycobacterial species and is a
highly expressed protein in Mtb and M. smegmatis (unpub-
lished data). KatG is an important virulence factor that pro-
vides protection from the deleterious effects of peroxide,
allowing survival of mycobacterial organisms inside mac-
rophages (23). Isoniazid, a frontline antimycobacterial agent,
requires conversion to its active form by KatG before it has
antimycobacterial effects (24, 25). Total or partial deletion of
katG as well as mutations that inactivate it lead to isoniazid
resistance (24, 26, 27). Although the crystallographic struc-
ture of mKatG has not yet been reported, there is strong ev-
idence that the enzyme is a homodimer in its native form,
with mutant forms displaying differences in electrophoretic
mobility and enzymatic function (21, 22).
The presence of KatG protein and DNA from Mtb or
possibly M. smegmatis in sarcoidosis tissues indicates that pre-
vious exposure to these organisms or closely related myco-
bacterial organisms occurs in a subset of patients with sarcoi-
dosis. The results of this study follow previous reports that
remnants of mycobacterial organisms are present in sarcoido-
sis tissues assessed by biochemical or immunohistochemical
techniques (28, 29). In one study, both cross-reactive and
Figure 5. Cellular localization of Mtb 16S rRNA DNA by ISH. 
Shown are representative photomicrographs from biopsies of Mtb-infected 
tissue (A and B), normal controls (no pathology; C and D), Wegener granu-
lomatosis (E and F), and sarcoidosis tissues (G–J). Tissue sections were 
hybridized with or without DIG-labeled probes, detected with anti-DIG 
F(ab )2 fragments conjugated with alkaline phosphatase, and developed 
with Vector Red substrate. Mtb-infected tissue (A) and sarcoidosis samples 
(G and I) demonstrated focal collections of Mtb 16S rRNA DNA that were 
not seen in Wegener granulomatosis (E) nor in nongranulomatous control 
tissues (C). All tissues were negative using reverse Mtb 16S rRNA probes.JEM VOL. 201, March 7, 2005 763
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species-specific antigenic determinants from Mtb proteins
and cell wall products were found in Schaumann bodies in
sarcoidosis tissue by immunohistochemistry (29). Multiple
PCR-based studies report widely varying results with traces
of mycobacterial nucleic acids detected in 0–80% of sarcoi-
dosis tissues (30–34). In a recently reported study, Drake et
al. (35) reported detecting mycobacterial rRNA or rpoB se-
quences in 60% of sarcoidosis tissues but in none of the
control tissues. Consistent with these results, we detected
mKatG and Mtb. 16S rRNA DNA in a subset of sarcoidosis
tissues using ISH techniques. These data strengthened the
initial findings from our limited proteomic approach and
together provided new evidence for the hypothesis that ex-
posure to mycobacterial organisms may trigger sarcoidosis in
a subset of patients (36).
Additional support for a mycobacterial etiology of sarcoi-
dosis is provided by our finding that the proportion of sar-
coidosis patients with circulating antibodies to mKatG was
similar to PPD  subjects with either previous wild-type ex-
Table IV. Circulating IgG responses to recombinant mKatG and mHsp65 in sarcoidosis patients and PPD  and PPD  
control subjects
mKatG mHsp65 mKatG mHsp65
80 kD 60 kD 65 kD CXR stagea 80 kD 60 kD 65 kD
Sarcoidosis PPD 
S1  b    2N 1     
S2      2N 2     
S3      1N 3     
S4      2N 4     
S5      2N 5     
S6      1N 6     
S7      2N 7     
S8      2N 8     
S9      2N 9     
S10      2 N10     
S11      1 N11     
S12      1 PPD 
S13      1P 1        
S14      1P 2     
S15      3P 3     
S16      1P 4     
S17      2P 5     
S18      3P 6     
S19   c    0P 7     
S20        2P 8     
S21      2P 9     
S22      1 P10     
S23      1
S24      0
S25      1
aStage 0, normal chest radiograph; stage 1, bilateral hilar adenopathy; stage 2, bilateral hilar adenopathy plus interstitial infiltrates; stage 3, pulmonary infiltrates only (no hilar 
adenopathy).
bTiter 1:500.
cTiter .1:1,000.
Figure 6. Circulating IgG from patients with sarcoidosis binds to 
recombinant mKatG and mHsp65 protein. Protein immunoblots with 
recombinant mKatG (A) or mHsp65 (B) were analyzed with IgG purified 
from the sera of healthy PPD  (N), PPD  (P) subjects or sarcoidosis (S) 
patients corresponding to Table IV. Arrowheads demark migration of mol 
wt markers (top to bottom: 188, 62, 49, and 38 kD). Arrows demark  80- 
and  60-kD antigenic bands reactive to mKatG or a 65-kD band reactive 
to mHsp65.MYCOBACTERIAL CATALASE–PEROXIDASE IN SARCOIDOSIS | Song et al. 764
posure to Mtb or previous Bacille Calmette-Guerin (BCG)
vaccination. This proportion was significantly higher than in
PPD  subjects, suggesting that mKatG is a specific immuno-
logic target common to a subset of PPD  individuals and sar-
coidosis patients. This conclusion is bolstered by our finding
that all sarcoidosis patients with circulating antibodies to
mKatG also had circulating antibodies directed against
mHsp65, indicating that these patients have serologic reac-
tivity to mycobacterial antigens that extend beyond mKatG.
The proportion of sarcoidosis patients with reactivity to
mHsp65 but not mKatG was similar to that found in PPD 
controls, consistent with a nondisease-specific immunologic
reactivity or cross-reactivity to mHsp65 in these subjects as
has been reported previously (37, 38). Within the PPD 
group, serologic reactivity to mHsp65 was more frequent
than reactivity to mKatG, suggesting that mHsp65 might be
a more dominant immunologic target than mKatG in BCG-
vaccinated individuals or those with latent Mtb. Whether
differences in the immune responses to these specific myco-
bacterial proteins play a role in determining clinical out-
comes after mycobacterial exposure remains unknown.
Given the lack of correlation between mKatG reactivity and
clinical course in our series, it appears likely that the pres-
ence of anti-mKatG IgG responses does not determine clini-
cal outcome by itself in sarcoidosis.
The presence of mycobacterial proteins in sarcoidosis tis-
sues might be relevant to long-term immunologic stimula-
tion as a result of either antigen persistence or from the de-
velopment of autoimmunity by molecular mimicry (39–41).
Our findings that mKatG is often present in sarcoidosis tis-
sues at time of diagnosis and might be associated with anti-
mKatG responses suggests that antigen persistence plays a
role by promoting local adaptive immune responses associ-
ated with active granuloma formation in sarcoidosis. Because
mKatG is not known to be inherently resistant to protease
digestion, our findings suggest that mKatG is denatured in
vivo and complexed with poorly soluble tissue components
that provide relative protection against protease attack.
These protein/tissue aggregates may serve as an antigenic
reservoir for eventual degradation by dendritic cells or other
mononuclear phagocytes with subsequent antigen presenta-
tion of derived peptides (42, 43). The potential for mKatG
to serve as a target antigen in sarcoidosis is supported by our
preliminary studies that mKatG complexed to Sephadex
beads strongly induces granuloma formation in a previously
described rodent model of granulomatous inflammation (un-
published data and references 10, 44, and 45).
Although this study identified mKatG as one target of
the adaptive immune response in sarcoidosis, other poorly
soluble, protease-resistant tissue antigens have not yet been
identified. Because mKatG was found in only a subset of tis-
sues, it is plausible, if not likely, that other microbial antigens
or endogenous proteins as autoantigens promote local adap-
tive immune responses as part of the pathogenic granuloma-
tous inflammation in other groups of sarcoidosis patients.
The identification of these other tissue antigens has been im-
peded by the small amounts of tissue that are obtained dur-
ing standard biopsy procedures and the resulting trace
amounts of protein antigens isolated in a mixture with other
tissue components. Despite the inherent difficulties in deter-
mining the identity of these tissue antigens, results from this
study suggest that there might be only a small number of tis-
sue antigens that are specific targets of an adaptive humoral
response associated with granulomatous inflammation in sar-
coidosis. More generally, the identification of mKatG as a
target tissue antigen supports the concept that granulomas in
sarcoidosis contain pathobiologically relevant antigens capa-
ble of reconstructing the natural history of sarcoidosis. Iden-
tification of other disease-specific tissue antigens is likely to
provide further insight into the etiopathogenesis of sarcoido-
sis and demonstrate the feasibility of using this type of lim-
ited proteomic approach to detect pathogenic antigens in
other human granulomatous diseases.
MATERIALS AND METHODS
Patient populations. Tissue specimens were obtained from two sources.
First, portions of tissue biopsies from patients with suspected sarcoidosis
who were undergoing diagnostic procedures were prospectively collected
with patient consent under an institutional review board (IRB)-approved
protocol if part of the biopsy sample was not needed for clinical purposes.
Second, archived surgical specimens from patients with confirmed sarcoido-
sis or from control groups from The Johns Hopkins Hospital or Mount Si-
nai Medical Center were obtained with IRB approval within institutional
guidelines for the use of archived tissues. All tissues were processed similarly
after surgical biopsy with unused fresh frozen or fixed, paraffin-embedded
tissue used for research only after confirmation of a clinical and pathologic
diagnosis. Sarcoidosis tissues were from patients with a final diagnosis of sar-
coidosis based on clinical criteria and biopsy showing typical noncaseating
epithelioid granulomas without evidence of bacterial, mycobacterial, or
fungal organisms using standard special stains (Kinyoun’s acid fast, auramine
rhodamine, and Gomori’s methanamine silver stains) or culture in accor-
dance with consensus criteria (1). Control lymph node tissues were from
patients who had undergone surgical biopsy or resection to exclude malig-
nancy or evaluate lymphadenopathy of unknown cause. In all but two cases,
the samples showed no evidence of malignancy, infection, or granuloma.
Two lymph nodes demonstrated follicular hyperplasia that were consistent
with a clinical diagnosis of an autoimmune disease. Control lung tissues
were from patients with biopsy-proven Wegener granulomatosis, usual in-
terstitial pneumonia, or without pathology (no evidence of malignancy, in-
fection, or granuloma) from patients who had undergone biopsy to exclude
malignancy. Control spleen tissues were obtained from splenectomy samples
from patients who had undergone surgery for abdominal malignancy.
Peripheral blood for sera was obtained from patients with biopsy-
proven sarcoidosis, PPD  healthy controls, and PPD  subjects. All patients
were recruited under IRB-approved protocols. A diagnosis of sarcoidosis
was based on a compatible clinical history and biopsy according to consen-
sus criteria (1). 6 patients had clinical evidence for pulmonary involvement
only and 19 patients had clinical evidence of extrapulmonary disease with or
without pulmonary involvement, consistent with published criteria (1, 46).
Chest radiograph staging was determined according to international con-
vention (1). Based on clinical presentation and chest radiograph, all patients
had active sarcoidosis at time of phlebotomy (1).
The PPD  group of control subjects either had a history of BCG vacci-
nation or had known or presumed prior infection with Mtb. Standard PPD
skin testing using intradermal injection of 5 tuberculin units of PPD (Tu-
bersol; Aventis Pasteur) was performed to confirm the status of self-reported
PPD  volunteers (47). Responses to PPD were assessed as largest diameter
of induration present 48 h after injection. For the purposes of this study, in-JEM VOL. 201, March 7, 2005 765
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duration of  10 mm at the time of follow-up examination was considered a
positive skin test response.
Reagents. TX100, n-laural sarkosine (sarkosyl), micrococcal nuclease, and
PK were purchased from Sigma-Aldrich and were of the highest quality
available. Recombinant Hsp65 from batch number MA-11A was obtained
from M. Singh (World Health Organization [WHO], Braunschweig, Ger-
many) from the WHO Recombinant Protein Bank with financial support
from the UNDP/World Bank/WHO Special Program for Research and
Training in Tropical Diseases.
mAb IT57, reactive to mKatG, was obtained from Colorado State
University and was produced through funds from the National Institutes of
Health (NIH), National Institute of Allergy and Infectious Diseases (con-
tract N0-AI-75320 entitled “Tuberculosis Research Materials and Vaccine
Testing”; reference 20).
TX100 extraction. Tissues were processed according to protocols similar
to ones that were previously reported to preserve and concentrate the in
vivo granuloma-inducing activity of sarcoidosis tissue homogenates (13, 17,
18). In brief, samples of frozen lymph node, spleen, or lung ranging from
0.1–2 g total weight were homogenized at a ratio of 1:10 in PBS, pH 7.4,
using a polytron with five to six 10-s bursts on medium speed. The suspen-
sion was centrifuged at 500 g for 10 min, and the supernatant was saved.
The pellet was resuspended in PBS and the homogenization procedure was
repeated. The supernatants were pooled and centrifuged at 22,000 g (16,000
rpm; T-30 rotor) for 40 min. The pellets were resuspended in PBS, centri-
fuged at 22,000 g for 30 min, washed in PBS, resuspended, sonicated twice
for  1 min each, and forced through 100-wire mesh. The suspension was
again sonicated, centrifuged at 22,000 g for 30 min, and the supernatant was
removed to collect the pellet (P22). The pellet was stored overnight at 4 C
and then resuspended in PBS and diluted to a concentration of  100 mg/
ml. TX100 (a final concentration of 2%) was added to 400  l of this suspen-
sion in a microfuge tube, and the suspension was shaken for 2 h at 37 C. 10
U/ml micrococcal nuclease was added and the suspension was shaken for
3 h at 37 C. The suspension was divided into two 200- l aliquots, one of
which received 100  g/ml PK. Both aliquots were rotated for 16 h at room
temperature, and then the reaction was stopped by adding 0.2 mM PMSF
to each aliquot. The aliquots were extracted with a 1:1 solution of 2:1 chlo-
roform/methanol by continuous rotation for 30 min and spun in a mi-
crofuge tube at 12,000 rpm. The pellets were washed in ice-cold 80%
methanol for 30 min, spun for 30 min at 12,000 rpm, and the pellets were
washed again in ice-cold 80% ethanol. After a 30-min centrifugation in a
microfuge at 12,000 rpm, the resultant pellet was resuspended in 170  l 8 M
urea plus 0.1 M  -mercaptoethanol in 0.1 M sodium phosphate Tris buffer,
pH 7.4, plus 0.2 mM PMSF for 20 h at 4 C. After centrifugation in a mi-
crofuge at 12,000 rpm for 30 min, the supernatant was collected, precipi-
tated with nine volumes of 1:2 chloroform/methanol for 30 min on ice,
spun at 12,000 rpm, and then washed in ice-cold methanol and ethanol as
detailed above. The final pellets were either analyzed directly by SDS-
PAGE or lyophilized and stored at  80 C for later analysis.
Sarkosyl extraction. To enrich for poorly soluble protein aggregates, a
moderately denaturing detergent extraction was used that previously had
been used to enrich for prion protein aggregates (19). Tissue samples of
1.7–5 g total weight were homogenized as described above and processed
to yield PBS-insoluble tissue pellets (P22), which were stored at  80 C until
use. The pellets (P22) were thawed and resuspended in 12–24 ml of 1% sar-
kosyl in PBS at a concentration of  100 mg/ml, ultrasonicated intermit-
tently for 1 min followed by mixing for 1 h, and then centrifuged at 22,000 g
for 20 min. The resultant supernatant (S22) was centrifuged at 215,000 g
(46,000 rpm with a Ti60 rotor) for 2 h. The pellet (P215) was resuspended
in buffer (1% sarkosyl, 10% NaCl, 50 mM Tris, pH 7.4) and spun at
215,000 g for 2.5 h. The pellet was collected, resuspended in the same
buffer (1% sarkosyl, 10% NaCl, 50 mM Tris, pH 7.4), and stirred overnight
at 37 C. The suspension was transferred to a microfuge tube, spun 20 min
at 12,000 rpm, and the pellet (P1) was resuspended in 1 ml buffer (0.2% sar-
kosyl, 10% NaCl, 50 mM Tris, pH 7.4) with shaking at 37 C for 1 h. The
pellets (P2) were resuspended in 1 ml buffer (0.1% sarkosyl in 50 mM Tris,
pH 7.4) and shaken at 37 C for 1 h. The samples were spun for 20 min in a
microfuge at 12,000 rpm and the process was repeated. The resulting pellet
was resuspended in a microfuge tube in 8 M urea, 0.1 M sodium phosphate,
Tris 7.4 buffer plus 0.1 M  -mercaptoethanol, and gently shaken overnight
at 4 C. The samples were then spun in a microfuge at 12,000 rpm, and the
supernatant was precipitated with 1:1 chloroform/methanol (1:2) followed
by washing the pellet in 80% ethanol as detailed above to yield the final pel-
let (Pe). The pellets were either used directly in gel electrophoresis or ly-
ophilized and stored at 4 C for later analysis.
Protein immunoblot. Total protein content was analyzed by the bi-
cinchroninic acid method for colorimetric detection and quantification
(BCA Protein Assay Kit; Pierce Chemical Co.). Protein samples were ana-
lyzed by gel electrophoresis using either 10–20% Tris-HCl SDS-PAGE
(Bio-Rad Laboratories) or 4–12% NuPAGE Bis-Tris gels (Novex) accord-
ing to the manufacturer’s recommendations. Gels were stained with either a
silver stain or Coomassie Brilliant Blue colloidal stain (Sigma-Aldrich). Gels
were electroblotted onto nitrocellulose membranes (Schleicher and Schuell)
according to manufacturer’s recommendations. Immunoblots were preincu-
bated with nonfat dried milk dissolved in TTBS (2% dry milk/0.1% Tween
20 in PBS), and then primary antibodies were added. Protein immunoblots
were probed with either total IgG or F(ab )2 fragments derived from pooled
sera from one of three sets of five to six individual sarcoidosis patients or
two sets of control sera. Total IgG was purified by Protein A affinity Pak
(Pierce Chemical Co.) chromatography according to the manufacturer’s
recommendations. F(ab )2 fragments were derived from total IgG by using
the ImmunoPure F(ab )2 preparation kit (Pierce Chemical Co.) with immo-
bilized pepsin bound to beaded agarose, according to the manufacturer’s
recommendations. Secondary antibody reagents were anti–human Fab or
Fc  (Sigma-Aldrich) linked to horseradish peroxidase (HRP) detected with
the ECL system (Amersham Biosciences). Immunoblots were stripped of
their primary antibody by agitating in stripping solution (100 mM 2-mecap-
toethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.7) for 30 min at 50 C or by
Restore Western Blot stripping buffer (Pierce Chemical Co.) according to
the manufacturer’s recommendations.
MALDI-TOF mass spectroscopy. Samples were run on 4–12% Nu-
PAGE Bis-Tris gels (Novex) and stained with a Coomassie Brilliant Blue
colloidal stain. Protein bands were excised based on migration of mol wt
markers. Proteins in the excised bands were digested with trypsin in situ,
and the resulting peptides were extracted, precipitated under low and high
salt conditions, and analyzed by MALDI-TOF mass spectrometry as de-
scribed previously (48, 49). In brief, gel slices were placed into an Eppen-
dorf tube with a ratio of 1:1 (vol/vol) acetonitrile/25 mM ammonium bi-
carbonate added for 30 min or until the majority of blue dye was removed.
The gel slice was dried completely under vacuum. 2  L trypsin solution
(0.1  g/ L in 1% acetic acid) and 25  l of buffer (25 mM ammonium bi-
carbonate) were added, and the reaction mixture was incubated at 37 C
overnight. The tryptic fragments were extracted twice from the gel by add-
ing 30  l of 1:1 (vol/vol) acetonitrile/water, 5% trifluoroacetic acid. The
extraction mixture was dried under a vacuum to an approximate volume of
5  L. The reaction mixture (0.3  L) was deposited onto a stainless steel
sample probe followed by 0.3  l of saturated  -cyano-4-hydroxycinnamic
acid matrix (1:1 vol/vol ethanol/water). Mass spectra were acquired on a
Kratos Kompact MALDI 4 time of flight mass spectrometer equipped with
a nitrogen laser (337 nm). Mass spectra were calculated using trypsin autoly-
sis peaks or internal standards.
The peptide mass fingerprint was analyzed by protein database se-
quence searching using the OWL database and the MOWSE-based search
engine using Protein Prospector at the University of California, San Fran-
cisco web site (http://prospector.ucsf.edu) or the Mascot search engine
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Overexpression and purification of mKatG. mKatG protein was
overexpressed from the plasmid construct pYZ56, which contained the
katG gene in a 2.9-kD EcoRV–KpnI fragment in pUC19 vector (24). The
KatG protein forms a fusion protein with 22 amino acids of the lacZ gene,
and the overexpression was driven by the lacZ promoter on the pUC19.
The pYZ56 construct was transformed into the E. coli catalase mutant UM2
and the transformant was grown in LB medium containing 50  g/ml ampi-
cillin overnight (24). Protein extracts were prepared by sonication on ice,
and the purification of the KatG protein was performed as described by
Johnsson et al. (51). For protein immunoblots, recombinant mKatG was
precipitated in 80% ethanol overnight, and the mixture was centrifuged in a
microfuge at 12,000 rpm for 20 min. The pellet was then resuspended in
loading buffer and used in protein immunoblot procedures.
Bacterial extract preparation. Bacterial and mycobacterial cultures were
grown to early stationary phase, centrifuged, and cell pellets were washed
twice with PBS. The cells were then resuspended in PBS, and soluble pro-
tein extracts were prepared by sonication followed by centrifugation.
ISH with TSA. To detect the presence of mkatG DNA in paraffin-
embedded archival biopsy tissue samples, we performed ISH with TSA us-
ing a manufacturer’s reagents and protocol (GenPoint kit K0620; DakoCy-
tomation) modified for use with digoxigenin (DIG)-tailed probes (52–54).
The presence of mycobacterial DNA in tissue samples was also evaluated
using ISH without TSA using Mtb 16S rRNA probes.
Oligonucleotide probes specific for mkatG (gcccaaggtatctcgcaacg; Gen-
Bank accession no. 488449) or Mtb16S rRNA (accggcttttaaggattcgctta;
GenBank accession no. 44689) were designed using the online NCBI
BLAST tool (Blast2seq). Reverse sequence oligonucleotides from mkatG or
Mtb 16S rRNA probes or H. pylori 16S rRNA (ggacataggctgatctcttagc; Gen-
Bank accession no. 21314562) were used as controls. Probes were 3  end la-
beled with DIG-11-dUTP (DIG oligonucleotide tailing kit; Roche Applied
Science) and diluted with hybridization buffer (S3304; DakoCytomation) to
a final concentration of 100 nM.
ISH-TSA was performed with 8- m slides that were deparaffinized,
treated with target retrieval solution (S1700; DakoCytomation) in a steamer
for 20 min, and digested with PK (S3004; DakoCytomation) diluted at
1:2,500 for 5 min. Background peroxidase activity was quenched with 0.3%
hydrogen peroxide in methanol, and the slides were air-dried. 20–40  l of
probe mixture was placed onto sections, the slides were coverslipped,
heated to 97 C for 5 min, and then immediately placed into a humidified
oven and incubated for 18 h at 56 (mkatG probes), 58 (Mtb 16S rRNA
probes), or 37 C (H. pylori 16s rRNA probes). Sections were rinsed with
PBS with 0.05% Tween-20, washed twice with stringent wash solution
(GenPoint kit; DakoCytomation) at the appropriate temperature (56 C for
mkatG, 63 C for Mtb 16S rRNA, or 45 C for H. pylori 16S rRNA), and
then incubated with rabbit F(ab )2 anti-DIG antibodies conjugated to HRP
(DakoCytomation). Signal amplification was performed by incubation with
biotinylated tyramine. After a final wash, sections were incubated with
streptavidin conjugated to HRP. Hybridized sections were developed with a
DAB chromogen solution followed by counterstaining with hematoxylin.
ISH without TSA was performed by incubation with sheep F(ab )2 anti-
DIG antibodies conjugated with alkaline phosphatase (Roche). After a final
wash, sections were developed with Vector Red substrate (Vector Labora-
tories) and counterstained with hematoxylin.
Tissue sections were examined under low (100 ) and high power
(400 ) light microscopy. Positive control tissues included two archived bi-
opsy samples from patients with culture-positive Mtb infection and com-
mercially available slides with mycobacterial infection approved for clinical
laboratory use (Histology Control Systems, Inc. and Sigma-Aldrich). All ar-
eas involved with inflammation (Mtb, sarcoidosis, Wegener granulomatosis,
and usual interstitial pneumonia) or nondiseased areas of no-pathology con-
trol tissues were examined for focal collections of stain (a minimum of 10
high power fields). Based on analyses of reverse probe controls and known
mycobacterial infected control tissues, the following criteria were estab-
lished: the presence of  0.5 stained foci per 10 high power fields was inter-
preted as “negative”; the presence of 0.5–1.0 stained foci per 10 high power
fields was read as “indeterminate”; and the presence of  1.0 stained foci per
10 high power fields was read as “positive.”
Statistical analysis. Comparisons were performed by Chi-square analysis
with the two-tailed Fisher’s exact test using JMP Statistical Discovery Soft-
ware, version 5 (SAS Institute, Inc.). A probability value of P   0.05 was
considered significant.
Online supplemental material. Tables S1 and S2 provide summaries of
potential peptide matches for Mtb topoisomerase I and M. smegmatis KatG
from MALDI-TOF mass spectrometry of sarcoidosis tissues. Fig. S1 shows a
representative protein immunoblot of recombinant mKatG and sonicated
cell-free extracts of Mtb, M. smegmatis, M. chelonei, H. pylori, and E. coli us-
ing the anti-mKatG IT57 mAb. Tables S1, S2, and Fig. S1 are available at
http://www.jem.org/cgi/content/full/jem.20040429/DC1.
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